RxDoctor Payments Data

John Adams, MD

Internal Medicine · Elgin, SCNPI 1750395570

Payments from drug & device makers

$8,125in general payments, 2019–2025

Across 468 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$965
  • AbbVie$818
  • Teva Pharmaceuticals USA, Inc.$808
  • Pfizer$520
  • Lilly USA, LLC$487
  • Biosense Webster, Inc.$447
  • plus $4K from 37 others

What the payments were for

  • Travel & lodging$4475%
  • Food & beverage$7,67494%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,125 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$84,542
Medicare patients
255
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$51,397
JardianceEmpagliflozin32$40,769
EliquisApixaban42$29,314
TrulicityDulaglutide19$28,065
JanuviaSitagliptin Phosphate36$25,793
FarxigaDapagliflozin Propanediol34$23,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,761
XareltoRivaroxaban14$16,183
LinzessLinaclotide16$14,134
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,187
Breo ElliptaFluticasone/Vilanterol17$6,492
Albuterol Sulfate HfaAlbuterol Sulfate162$5,993
TradjentaLinagliptin12$5,927
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen239$5,702
Tresiba Flextouch U-100Insulin Degludec11$5,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$340$51,39742 claims
Boehringer IngelheimJardiance, Tradjenta$166$46,69644 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$965$36,04160 claims
PfizerEliquis$520$29,31442 claims
Lilly USA, LLCTrulicity$487$28,06519 claims
MerckJanuvia$127$25,79336 claims
Johnson & JohnsonXarelto$301$16,18314 claims
AbbVieLinzess, Synthroid$818$16,04741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Elgin

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →